DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
PHA-793887 is an investigational drug.
There have been 29 clinical trials for PHA-793887. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2014.
The most common disease conditions in clinical trials are Thymoma, HIV Infections, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.
There are two US patents protecting this investigational drug and fifty international patents.
Recent Clinical Trials for PHA-793887
|The Benefit of Bermekimab in Patients With Systemic Sclerosis||Hellenic Institute for the Study of Sepsis||Phase 2|
|ACTH vs Betamethasone in Hospitalized Patients With Acute Gout||University of Patras||N/A|
|The Effects of Nanocurcumin on Serum miRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients||Stem Cell and Regenerative Medicine Institute, Tabriz, Iran||Phase 2|
Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PHA-793887||Start Trial||Maturation of hepatocyte-like cells derived from human pluripotent stem cells||Takara Bio Europe AB (Gothenburg, SE)||Start Trial|
|PHA-793887||Start Trial||Substituted pyrrolo-pyrazole derivatives as kinase inhibitors||Pfizer Italia S.r.l. (Rome, IT)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PHA-793887||European Patent Office||2925859||2032-11-29||Start Trial|
|PHA-793887||European Patent Office||3401391||2032-11-29||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|